Emergent Biosolutions Inc. (NYSE:EBS – Get Free Report) has earned a consensus rating of “Hold” from the five analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $12.00.
EBS has been the subject of several recent research reports. HC Wainwright lowered their price objective on Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating for the company in a research report on Monday, March 9th. Wall Street Zen downgraded shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Weiss Ratings downgraded shares of Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. UBS Group reiterated a “buy” rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. Finally, Benchmark reissued a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd.
View Our Latest Research Report on Emergent Biosolutions
Emergent Biosolutions Stock Up 0.1%
Emergent Biosolutions (NYSE:EBS – Get Free Report) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.46. Emergent Biosolutions had a positive return on equity of 10.76% and a negative net margin of 1.27%.The company had revenue of $156.10 million during the quarter, compared to analysts’ expectations of $145.00 million.
Insider Buying and Selling at Emergent Biosolutions
In related news, Director Donald W. Degolyer sold 15,481 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $8.40, for a total value of $130,040.40. Following the sale, the director owned 129,721 shares in the company, valued at $1,089,656.40. This represents a 10.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn C. Zoon sold 17,202 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $8.40, for a total value of $144,496.80. Following the completion of the sale, the director owned 79,941 shares in the company, valued at $671,504.40. The trade was a 17.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 64,925 shares of company stock valued at $543,512. 6.00% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Emergent Biosolutions
Institutional investors have recently modified their holdings of the stock. Millennium Management LLC increased its holdings in shares of Emergent Biosolutions by 68.9% during the first quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock valued at $12,162,000 after acquiring an additional 1,020,582 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Emergent Biosolutions by 12.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,090,655 shares of the biopharmaceutical company’s stock valued at $5,301,000 after purchasing an additional 121,583 shares during the last quarter. Legal & General Group Plc purchased a new stake in Emergent Biosolutions during the 2nd quarter valued at about $31,000. Rhumbline Advisers grew its position in Emergent Biosolutions by 862.4% during the 2nd quarter. Rhumbline Advisers now owns 84,025 shares of the biopharmaceutical company’s stock valued at $536,000 after purchasing an additional 75,294 shares during the last quarter. Finally, Jump Financial LLC bought a new stake in Emergent Biosolutions during the 2nd quarter valued at about $352,000. 78.40% of the stock is owned by hedge funds and other institutional investors.
Emergent Biosolutions Company Profile
Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.
Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.
Featured Articles
- Five stocks we like better than Emergent Biosolutions
- AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus
- Gold and Silver Recovery—3 Precious Metals Stocks for H2 2026
- Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst
- Why Kroger’s Giant Eagle Deal Could Change Everything
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.
